Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 25 versus DEMI REGROTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 25 versus DEMI REGROTON.
ALDORIL 25 vs DEMI-REGROTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
DEMI-REGROTON is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines (norepinephrine, dopamine, serotonin) from central and peripheral nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to reduced sympathetic outflow and vasodilation.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
One tablet orally once daily, each tablet containing 25 mg chlorthalidone and 0.125 mg reserpine.
None Documented
None Documented
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Terminal elimination half-life is 40-60 hours (mean 48 h), allowing once-daily dosing; steady state reached in 5-7 days
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination